Agios is the pioneering leader in PK activation and dedicated to developing transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class PK activator for adults with PK deficiency. Building on its scientific expertise in classical hematology and cellular metabolism, Agios is advancing a robust pipeline of investigational medicines in α- and β-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria.
Agios is a biopharmaceutical company cultivating strong bonds with patient communities, healthcare professionals and partners to deliver therapies for rare diseases. Agios markets a first-in-class pyruvate kinase (PK) activator for treatment of hemolytic anemia in adults with PK deficiency in the US. Agios is advancing a clinical pipeline of investigational medicines with programs in α- and β thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. Visit agios.com.